Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIDL Chemotherapy and ASCT in Advanced Extranodal NK/T-Cell Lymphoma
NCT02544425Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2016
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, ifosfamide, dexamethasone, asparaginase escherichia coli in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
etoposideifosfamidedexamethasoneasparaginase escherichia coli
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02544425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544425.